Inflammatory breast cancer (IBC) comprises a small subset of all breast cancer diagnoses in the United States but contributes up to 10% of breast cancer mortality. Key clinical outcome measures, such as overall survival (OS), are significantly worse for IBC compared to non-IBC (Wingo, Jamison, Young, & Gargiullo, 2004). Using data from Surveillance, Epidemiology and End Results Program (SEER) and North American Association of Central Cancer Registries gathered over the past 30 years, we see an increasing incidence of IBC, which has more than doubled compared to non-IBC (Chang, Parker, Pham, Buzdar, & Hursting, 1998). Despite this increase, OS has changed only slightly over the same period. The local-regional control (LRC) rates in IBC have remained relatively constant so any change in OS can be assumed to be primarily attributable to recent advances in systemic chemotherapy (Gonzalez-Angulo et al., 2007). These observations highlight the need for improved local-regional treatment techniques to continue maximizing clinical outcomes for patients with IBC.